Botensilimab, an Fc-enhanced anti-CTLA-4 antibody, is effective against tumors poorly responsive to conventional immunotherapy
Chand, Dhan, Savitsky, David A, Krishnan, Shanmugarajan, Mednick, Gabriel, Delepine, Chloe, Garcia-Broncano, Pilar, Soh, Kah Teong, Wu, Wei, Wilkens, Margaret K, Udartseva, Olga, Vincent, Sylvia, Joshi, Bishnu, Keith, Justin G, Manrique, Mariana, Marques, Marilyn, Tanne, Antoine, Levey, Daniel L, Han, Haiyong, Ng, Serina, Ridpath, Jackson, Huber, Olivia, Morin, Benjamin, Galand, Claire, Bourdelais, Sean, Gombos, Randi B, Ward, Rebecca, Qin, Yu, Waight, Jeremy D, Costa, Matthew R, Sebastian-Yague, Alvaro, Rudqvist, Nils-Petter, Pupecka-Swider, Malgorzata, Venkatraman, Vignesh, Slee, Andrew, Patel, Jaymin M, Grossman, Joseph E, Wilson, Nicholas S, Von Hoff, Daniel D, Stebbing, Justin, Curiel, Tyler J, Buell, Jennifer S, O'Day, Steven J, Stein, Robert B
Published in Cancer discovery (31.07.2024)
Published in Cancer discovery (31.07.2024)
Get full text
Journal Article